HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 701–800 of 1,008
Giannoulis, A., Feintuch, A., Barak, Y., Mazal, H., Albeck, S., Unger, T., Yang, F., Su, X., & Goldfarb, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916030116 · Cited by 55
Natural Product Inhibitors of Hsp90: Potential Leads for Drug Discovery
Amolins, M. W., & Blagg, B. S. J. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787316056 · Cited by 57
Somu, P., Mohanty, S., Basavegowda, N., Yadav, A. K., Paul, S., & Baek, K.-H. (2024) · Cancers · doi:10.3390/cancers16030638 · Cited by 50
“…of newly synthesized proteins, restoration of denatured proteins to their functional states, directing proteins to specific cellular compartments, averting the aggregation of proteins, facilitating the maturation of signaling proteins, and orchestrating the regulated degradation of proteins [155].”
BackgroundFunctions of the Hsp90 chaperone system: lifting client proteins to new heights.
Eckl, J. M., & Richter, K. (2013) · Europe PMC (PubMed Central) · Cited by 65
Lim, K.-H., Kim, K., Choi, S. I., Park, E., Park, S. H., Ryu, K., Park, Y. K., Kwon, S. Y., Yang, S.-I., Lee, H. C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022258 · Cited by 53
“In addition, HSP90 is already a potential anti-cancer drug target and numerous small molecule inhibitors of HSP90, such as geldanamycin, have been developed and used in conjunction with other anti-cancer drugs, for combinational therapies [40,47].”
BackgroundEichner, S., Eichner, T., Floss, H. G., Fohrer, J., Hofer, E., Sasse, F., Zeilinger, C., & Kirschning, A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2087147 · Cited by 53
Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery
Audisio, D., Messaoudi, S., Cegielkowski, L., Peyrat, J., Brion, J., Methy‐Gonnot, D., Radanyi, C., Renoir, J., & Alami, M. (2011) · ChemMedChem · doi:10.1002/cmdc.201000489 · Cited by 53
Dixit, A., & Verkhivker, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037605 · Cited by 56
Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 55
Miles, J., Scherz‐Shouval, R., & van Oosten‐Hawle, P. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.06.009 · Cited by 55
Wolf, S., Amaral, M., Lowinski, M., Vallée, F., Müsil, D., Güldenhaupt, J., Dreyer, M. K., Bomke, J., Frech, M., Schlitter, J., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00592 · Cited by 60
Role of crocin in several cancer cell lines: An updated review.
Veisi, A., Akbari, G., Mard, S. A., Badfar, G., Zarezade, V., & Mirshekar, M. A. (2020) · PubMed Central · doi:10.22038/ijbms.2019.37821.8995 · Cited by 57
“Heat shock proteins (HSPs) have been found to be overexpressed in a wide variety of human carcinomas, including both solid tumors and hematological malignancies (115, 116).”
BackgroundNovel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
Allegra, A., Sant’Antonio, E., Penna, G., Alonci, A., D’Angelo, A., Russo, S., Cannavò, A., Gerace, D. G., & Musolino, C. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01558.x · Cited by 54
“[K(8)-ELP (1-60)]-GA conjugate nanoparticles showed a size ranging from 50 to 200 nm depending upon temperature.”
BackgroundInfluentialPost-translational modification of heat-shock protein 90: impact on chaperone function
Scroggins, B. T., & Neckers, L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.10.1403 · Cited by 52
London, C. A., Bear, M. D., McCleese, J., Foley, K. P., Paalangara, R., Inoue, T., Ying, W., & Barsoum, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027018 · Cited by 52
“In this state, a client protein associates with HSP90 with the help of co-chaperones such as p23, HSP40, HOP, and HIP[3,5,6].”
BackgroundInfluentialLipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Gajate, C., & Mollinedo, F. (2011) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489211796957766 · Cited by 54
“Raf-1, Bcr-Abl, and mutated p53 [90].”
Hsp90: Still a viable target in prostate cancer
Centenera, M. M., Fitzpatrick, A. K., Tilley, W. D., & Butler, L. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.005 · Cited by 53
Endocytic Down-Regulation of ErbB2 Is Stimulated by Cleavage of Its C-Terminus
Lerdrup, M., Bruun, S., Grandal, M. V., Roepstorff, K., Kristensen, M. M., Hommelgaard, A. M., & van Deurs, B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0025 · Cited by 60
“If the chaperone cycle is inhibited, e.g., by GA, then the cochaperone and ubiquitin ligase carboxyl terminus of HSP70-interacting protein (CHIP) is recruited to the ErbB2-associated chaperone complex stimulating ubiquitinylation of ErbB2 (Xu et al., 2002; Zhou et al., 2003; Whitesell and Lindquist, 2005; Caplan et al…”
BackgroundSynergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma
Calero, R., Morchon, E., Martínez‐Argudo, I., & Serrano, R. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.021 · Cited by 52
Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades
Srinivasan, S. R., Cesa, L. C., Li, X., Julien, O., Zhuang, M., Shao, H., Chung, J., Maillard, I. P., Wells, J. A., Duckett, C. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0408 · Cited by 52
“Hsp90 is known to play a similar functional role (12), yetmore is known about themechanisms by which that chaperone creates a nononcogene addiction.”
BackgroundmTORC1 Links Protein Quality and Quantity Control by Sensing Chaperone Availability
Qian, S.-B., Zhang, X., Sun, J., Bennink, J. R., Yewdell, J. W., & Patterson, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.120295 · Cited by 51
Kawashima, D., Kanda, T., Murata, T., Saito, S., Sugimoto, A., Narita, Y., & Tsurumi, T. (2013) · Journal of Virology · doi:10.1128/jvi.03428-12 · Cited by 55
“Hsp90 inhibitors are small molecules that specifically inhibit the Hsp90 chaperone machinery by binding to the ATP-binding domain (20).”
BackgroundSchwock, J., Pham, N., Cao, M. P.-J., & Hedley, D. W. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0522-8 · Cited by 56
“That this Rb-dependency might in fact be tumor/ cell-type speciWc has also been pointed out in a recent review by Whitesell and Lindquist [17].”
BackgroundResultInfluentialPan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances
Yu, J., Zhang, C., & Song, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114516 · Cited by 51
Therapeutic Targeting of DNA Replication Stress in Cancer
Gu, L., Hickey, R. J., & Malkas, L. H. (2023) · Genes · doi:10.3390/genes14071346 · Cited by 54
Wei, W., Wu, S., Wang, X., Sun, C. K.-W., Yang, X., Yan, X., Chua, M., & So, S. K. (2014) · Oncotarget · doi:10.18632/oncotarget.2171 · Cited by 52
“Lastly, CDC37 expression is increased in proliferating tissues and is heavily expressed in certain cancers (due to the increased need of over-expressed protein kinases that mediate their growth); whereas most normal tissues do not proliferate or appear to require CDC37 [10, 31].”
Liu, W., Zhang, F., Cai, M., Zhao, W.-L., Li, X.-R., Wang, J., & Zhao, X. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.037 · Cited by 51
Floris, G., Sciot, R., Woźniak, A., Looy, T. V., Wellens, J., Faa, G., Normant, E., Dêbiec‐Rychter, M., & Schöffski, P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0562 · Cited by 51
Molecular‐targeted nanotherapies in cancer: Enabling treatment specificity
Blanco, E., Hsiao, A., Ruiz‐Esparza, G. U., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.10.005 · Cited by 54
Design, synthesis, and evaluation of small molecule Hsp90 probes
Taldone, T., Zatorska, D., Patel, P. D., Zong, H., Rodina, A., Ahn, J. H., Moulick, K., Guzmán, M. L., & Chiosis, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.03.013 · Cited by 53
Inhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 54
“17-allylaminogeldanamycin, an oral inhibitor of Hsp90, has demonstrated in vivo efficacy in glioma models [143].”
BackgroundInfluentialmTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis
Acquaviva, J., He, S., Sang, J., Smith, D. L., Sequeira, M., Zhang, C., Bates, R. C., & Proia, D. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0605 · Cited by 51
“During tumorigenesis, the chaperoning activity of HSP90 may become subverted by cancer cells, in turn conferring aberrant proliferative, survival, angiogenic, and/or metastatic potential (6, 7).”
BackgroundGajate, C., & Mollinedo, F. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0215-055r · Cited by 54
“, protein kinase B), Raf-1, Bcr-Abl, and mutated p53, and is overexpressed in many tumor cells [167].”
BackgroundKimura, A., Ogata, K., Altan, B., Yokobori, T., Ide, M., Mochiki, E., Toyomasu, Y., Kogure, N., Yanoma, T., Suzuki, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7821 · Cited by 51
“HSPs were shown to be overexpressed in a wide range of human carcinomas, including both solid tumors and hematological malignancies [7, 12, 13].”
Overdosage of Balanced Protein Complexes Reduces Proliferation Rate in Aneuploid Cells
Chen, Y., Chen, S., Li, K., Zhang, Y., Huang, X., Li, T., Wu, S., Wang, Y., Carey, L. B., & Qian, W. (2019) · Cell Systems · doi:10.1016/j.cels.2019.06.007 · Cited by 53
Ojha, R., Nepali, K., Chen, C., Chuang, K.-H., Wu, T.-Y., Lin, T. E., Hsu, K., Chao, M., Lai, M.-J., Lin, M.-H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112086 · Cited by 52
Do, K. T., Speranza, G., Chang, L., Polley, E. C., Bishop, R. J., Zhu, W., Trepel, J. B., Lee, S., Lee, M.-J., Kinders, R. J., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0255-1 · Cited by 51
“Inhibition of Hsp90 leads to degradation of these aberrant proteins through the ubiquitin-proteosome pathway, allowing for simultaneous targeting of multiple pathways involved in the potentiation of cancer cells, forming the basis for inhibition of Hsp90 as an attractive anti-cancer therapy [3, 4].”
Hispolon promotes MDM2 downregulation through chaperone-mediated autophagy
Lu, T., Huang, G., Wang, H.-J., Chen, J.-L., Hsu, H., & Lu, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.004 · Cited by 53
Annamalai, B., Liu, X., Gopal, U., & Isaacs, J. S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0582 · Cited by 51
“The molecular chaperone heat shock protein 90 (Hsp90) facilitates the proper folding and conformation of its clients (31, 32).”
BackgroundChen, C., Jan, C.-I., Lo, J., Yang, S.-C., Chang, Y., Pan, S., Wang, W.-L., Hong, T.-M., & Yang, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4066 · Cited by 51
“EGFR is a client protein for HSP90 (7), which commonly functions in concert with various cochaperones including HSP70 and HSP40 (8).”
BackgroundRecent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
Sflakidou, E., Leonidis, G., Foroglou, E., Siokatas, C., & Sarli, V. (2022) · Molecules · doi:10.3390/molecules27196632 · Cited by 52
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer
Lai, C.-H., Park, K.-S., Lee, D., Alberobello, A. T., Raffeld, M. A., Pierobon, M., Pin, E., Petricoin, E. F., Wang, Y., & Giaccone, G. (2013) · Oncogene · doi:10.1038/onc.2013.439 · Cited by 51
“HSP90 is a chaperone protein which has multiple functions, and is involved in response to stress, posttranslational folding, stabilization of mutant oncogenic proteins 9 and plays critical roles in cell growth, differentiation and survival 10 .”
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
Goyal, L., Wadlow, R. C., Blaszkowsky, L. S., Wolpin, B. M., Abrams, T. A., McCleary, N. J., Sheehan, S., Sundaram, E., Karol, M. D., Chen, J. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0164-8 · Cited by 51
“Many of its client proteins, including the wild-type and/or activated forms of VEGFR, c-MET, HER2, EGFR, B-Raf, c-KIT, Akt, Cdk4, and PDGFRA, have been shown to be critical regulators of invasion, angiogenesis, and metastasis of tumors [14, 15].”
BackgroundProgress of molecular targeted therapies for prostate cancers
Fu, W., Madan, E., Yee, M., & Zhang, H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.11.003 · Cited by 55
“They play roles in a variety of cellular process including proliferation, differentiation, and survival by maintaining the stability of regulatory proteins [113].”
BackgroundZhang, C., Yang, Y., Zhou, X., Yang, Z., Liu, X., Cao, Z., Song, H., He, Y., & Huang, P. (2011) · Virology Journal · doi:10.1186/1743-422x-8-181 · Cited by 58
“Similar to other heat shock proteins, Hsp90 is a constitutively abundant molecular chaperone that controls the conformation, stability, activation, intracellular distribution, and turnover of numerous client proteins and involved in cell growth, differentiation, and survival [26,27].”
BackgroundLiu, X. Z., Chen, S., TU, J., Cai, W., & Xu, Q. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2482 · Cited by 56
“The protein and mRNA expression and levels of HSP90 have been shown to be upregulated in various types of cancers (9,29-32).”
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
Zhao, Z., Verma, V., & Zhang, M. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095407 · Cited by 54
“Hsp90 (heat shock protein 90) inhibitors induce fusion protein misfolding and subsequent degradation by the proteasome system.(113) Fusion proteins formed as the result of chromosomal rearrangements are thought to be particularly dependent on Hsp90 for protein folding, transport, and stability.”
BackgroundTargeting Cell Survival Proteins for Cancer Cell Death
Pandey, M. K., Prasad, S., Tyagi, A. K., Deb, L., Huang, J. M., Karelia, D. N., Amin, S., & Aggarwal, B. B. (2016) · Pharmaceuticals · doi:10.3390/ph9010011 · Cited by 56
Kendrick, A. A., Schafer, J. B., Dzieciątkowska, M., Nemkov, T. G., D’Alessandro, A., Neelakantan, D., Ford, H. L., Pearson, C. G., Weekes, C. D., Hansen, K. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14272 · Cited by 50
“com/oncotarget functions, and thus, chaperone interaction networks are often composed of many proteins [32].”
BackgroundLiu, J.-C., Narva, S., Zhou, K., & Zhang, W. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190312152358 · Cited by 53
Kosinsky, R. L., Helms, M., Zerche, M., Wohn, L., Dyas, A., Prokakis, E., Kazerouni, Z. B., Bedi, U., Wegwitz, F., & Johnsen, S. A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2141-9 · Cited by 51
Cancer extracellular vesicles, tumoroid models, and tumor microenvironment
Eguchi, T., Sheta, M., Fujii, M., & Calderwood, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.003 · Cited by 57
Remarkable Stereospecific Conjugate Additions to the Hsp90 Inhibitor Celastrol
Klaić, L., Trippier, P. C., Mishra, R. K., Morimoto, R. I., & Silverman, R. B. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208359a · Cited by 50
Role of the Cochaperone Tpr2 in Hsp90 Chaperoning
Moffatt, N., Bruinsma, E. S., Uhl, C. B., Obermann, W. M. J., & Toft, D. O. (2008) · Biochemistry · doi:10.1021/bi800770g · Cited by 50
Banz, V. M., Medová, M., Keogh, A., Furer, C., Zimmer, Y., Candinas, D., & Stroka, D. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.08.002 · Cited by 55
“an open, non-functional state that generally results in the degradation of client proteins via the ubiquitin–proteasome pathway [14,26,27].”
BackgroundKim, R. H., Kim, R., Chen, W., Hu, S., Shin, K.-H., Park, N.-H., & Kang, M. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn225 · Cited by 50
Larson, N., Greish, K. F., Bauer, H., Maeda, H., & Ghandehari, H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.011 · Cited by 49
“GDM binds to the N-terminal ATP-binding site of Hsp90 and induces degradation of its client proteins (Whitesell and Lindquist, 2005).”
BackgroundD’Aguanno, S., D’Alessandro, A., Pieroni, L., Roveri, A., Zaccarin, M., Marzano, V., Canio, M. D., Bernardini, S., Federici, G., & Urbani, A. (2010) · Journal of Proteome Research · doi:10.1021/pr100457n · Cited by 54
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target
Zappasodi, R., Bongarzone, I., Ghedini, G. C., Castagnoli, L., Cabras, A. D., Messina, A., Tortoreto, M., Tripodo, C., Magni, M., Carlo‐Stella, C., et al. (2011) · Blood · doi:10.1182/blood-2011-06-364570 · Cited by 49
“Surface (A) and intracellular (B) flow cytometric analyses of normal B cells, (1) low-grade B-cell NHL cell lines DOHH-2, (2) SC-1, (3) SU-DHL-6, and (4) KARPAS-422, (5) high-grade B-cell NHL cell lines RL-19, (6) SU-DHL-4, (7) RAJI, (8) NAMALWA, and (9) GRANTA-519, (10) Hodgkin lymphoma cell lines L-540 (11) and HDMY…”
BackgroundTargeting heat shock response pathways to treat pancreatic cancer
Xia, Y., Rocchi, P., Iovanna, J., & Peng, L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.016 · Cited by 52
Hao, Y., & Gu, X. (2014) · Poultry Science · doi:10.3382/ps.2014-03993 · Cited by 51
“The GA dissociates mature multi-chaperone complexes by inhibiting HSP90 ATPase activity, and the released client proteins are subsequently degraded by the ubiquitin-proteasome pathway (Whitesell and Lindquist, 2005).”
BackgroundHeat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity
Calderwood, S. K., Murshid, A., & Gong, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00075 · Cited by 55
“Accumulation of mutations in cancer appears to be related to, and may drive the increases in HSPs observed in many tumors (Kamal et al., 2003; Whitesell and Lindquist, 2005; Trepel et al., 2010).”
BackgroundAhmad, A., Mondal, S. K., Mukhopadhyay, D., Banerjee, R., & Alkharfy, K. M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00900 · Cited by 51
Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer
Hardin, C., Shum, E., Ap, S., Perez-Soler, R., & Cheng, H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1316374 · Cited by 51
“Heat shock protein 90 (hsp90) is a molecular chaperone that assists in normal cellular function including protein folding, intracellular management, turnover of cellular regulators, and interaction with multiple signal transduction pathways [125].”
BackgroundLi, T., Chen, X., Dai, X.-Y., Wei, B., Weng, Q., Chen, X., Ouyang, D., Yan, R., Huang, Z., Jiang, H., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.07.006 · Cited by 52
“Recently, the Hsp90 cycle has been discovered to involve complex formationwithmultiple co-chaperones, especially cell division cycle protein 37 (Cdc37) and co-chaperone-modulating interactions with kinases (Mayer, 2010; Verba et al., 2016; Whitesell and Lindquist, 2005).”
BackgroundA tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy
Huang, L., Wei, G., Sun, X., Jiang, Y., Huang, Z., Huang, Y., Shen, Y., Xu, X., Liao, Y., & Zhao, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.077 · Cited by 50
Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone
Bekeschus, S., Lippert, M., Diepold, K., Chiosis, G., Seufferlein, T. T. W., & Azoitei, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-38580-0 · Cited by 49
Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer
Park, S. H., Jeong, S., Kim, B. R., Jeong, Y. A., Kim, J. L., Na, Y. J., Jo, M. J., Yun, H. K., Kim, D. Y., Kim, B. G., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0972-6 · Cited by 57
Davies, N. G. M., Browne, H. L., Davis, B. J., Drysdale, M. J., Foloppe, N., Geoffrey, S., Gibbons, B., Hart, T. W., Hubbard, R. E., Jensen, M. R., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.050 · Cited by 55
Protein folding, protein homeostasis, and cancer
Drie, J. H. V. (2011) · 癌症:英文版 · doi:10.5732/cjc.010.10162 · Cited by 55
DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer
Zhang, M., Peng, Y., Yang, Z., Zhang, H., Xu, C., Liu, L., Zhao, Q., Jixiong, W., Wang, H., & Liu, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09596-z · Cited by 52
“and apoptosis of CRC cell lines induced by HSP90AA1 Recent studies have shown that the absence of DAB2IP or increased expression of HSP90 promotes malignant behavior in various tumors [23, 25].”
BackgroundHSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas
Ernst, A., Anders, H., Kapfhammer, H., Orth, M., Hennel, R., Seidl, K., Winssinger, N., Belka, C., Unkel, S., & Lauber, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.024 · Cited by 49
“HSP90 inhibition in general appears as a very attractive means of radiosensitization, since it can target multiple HSP90 client proteins orchestrating radioresistance and other characteristics of the malignant phenotype, including angiogenesis, invasiveness and metastasis, at the same time [28,30,45,46].”
BackgroundVallée, F., Carrez, C., Pilorge, F., Dupuy, A., Parent, A., Bertin, L., Thompson, F., Ferrari, P., Fassy, F., Lamberton, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200784m · Cited by 50
Targeted therapy in breast cancer: what’s new?
Li, F., Barekati, Z., Zhang, B., Liu, Z., & Zhong, X. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13231 · Cited by 56
Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Alarcon, S., Mollapour, M., Lee, M.-J., Tsutsumi, S., Lee, S., Kim, Y. S., Prince, T. L., Apolo, A. B., Giaccone, G., Xu, W., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306729 · Cited by 49
“The list of Hsp90 client proteins that are degraded in response to an Hsp90 inhibitor include many oncogenic fusion proteins, mutated and activated serine/threonine protein kinases, tyrosine kinases, and transcription factors with oncogenic activity [2, 20-22].”
BackgroundGlobal Targeting of Subcellular Heat Shock Protein-90 Networks for Therapy of Glioblastoma
Siegelin, M. D., Plescia, J., Raskett, C. M., Gilbert, C. A., Ross, A. H., & Altieri, D. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0097 · Cited by 48
“The second phenotype induced by Shepherdin involved acute inhibition of Hsp90 chaperoning in the cytosol (12, 13),with concomitant loss ofmultiple cytoprotective client proteins, including Bcl-2, XIAP, survivin, and Akt.”
Lee, S.-C., Min, H., Choi, H., Bae, S. Y., Park, K. H., Hyun, S. Y., Lee, H. J., Moon, J., Park, S., Kim, J. Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1492 · Cited by 51
“The C-terminal domain of Hsp90 is crucial for dimerization of Hsp90 (2, 29).”
InfluentialRosenberg, J. E., Hahn, N. M., Regan, M. M., Werner, L. L., Alva, A. S., George, S., Picus, J., Alter, R. S., Balar, A. V., Hoffman-Censits, J. H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0087-9 · Cited by 49
Transition metal-free assembly of 1,3,5-triazines using ethyl bromodifluoroacetate as C1 source
Yu, X., Zhou, Y., Ma, X., & Song, Q. (2019) · Chemical Communications · doi:10.1039/c9cc03534f · Cited by 48
Jafari, A., Rezaei–Tavirani, M., Farhadihosseinabadi, B., Taranejoo, S., & Zali, H. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1752227 · Cited by 49
“Elevated expression of HSP90 helps cancer cells to survive in poor physiological and stressful situations such as hypoxia, low pH, nutritional deficiencies, and exposure to chemicals or UV light (Figure 2) (9).”
BackgroundInfluentialMalenica, I., Donadon, M., & Lleò, A. (2020) · Cancers · doi:10.3390/cancers12082190 · Cited by 50
Sun, X., Bristol, J. A., Iwahori, S., Hagemeier, S. R., Meng, Q., Barlow, E. A., Fingeroth, J. D., Tarakanova, V. L., Kalejta, R. F., & Kenney, S. C. (2013) · Journal of Virology · doi:10.1128/jvi.01671-13 · Cited by 48
“in protein-protein interaction and intracellular trafficking (48, 87).”
BackgroundBurgess, E. F., Ham, A. L., Tabb, D. L., Billheimer, D. D., Roth, B. J., Chang, S. S., Cookson, M. S., Hinton, T. J., Cheek, K. L., Hill, S., et al. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200780073 · Cited by 48
“In our study, we chose to pursue validation of HSP90α, given its well-characterized role in the biology of various solid tumors [48].”
MethodCdc37 Regulation of the Kinome: When to Hold ‘Em and When to Fold ‘Em
Karnitz, L. M., & Felts, S. J. (2007) · Science's STKE · doi:10.1126/stke.3852007pe22 · Cited by 47
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
“Since the proteasome eliminates aberrant or damaged proteins that otherwise would be toxic for the cell, upregulation of proteasome activity could provide an advantageous feature for cancer cells to survive amidst proteotoxic conditions (Whitesell and Lindquist 2005).”
BackgroundKlinefelter, G. R., Laskey, J. W., Winnik, W., Suarez, J. D., Roberts, N. L., Strader, L. F., Riffle, B. W., & Veeramachaneni, D. N. R. (2012) · Reproduction · doi:10.1530/rep-12-0266 · Cited by 48
“Both HSP70 and 90 are known to complex with estrogen receptor (ER) to form a stable, high affinity estradiol-binding state (Whitesell & Lindquist 2005).”
BackgroundCombating neurodegenerative disease with chemical probes and model systems
Narayan, P. S., Ehsani, S., & Lindquist, S. L. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1663 · Cited by 60
Self-citationE3 ubiquitin ligases in ErbB receptor quantity control
Carraway, K. L. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.09.006 · Cited by 45
High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells
Tian, W., He, F., Fu, X., Lin, J., Tang, P., Huang, Y., Guo, R., & Sun, L. (2014) · Gene · doi:10.1016/j.gene.2014.03.046 · Cited by 49
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile
Speranza, G., Anderson, L. D., Jr., Chen, A. P., Do, K. T., Eugeni, M. A., Weil, M. K., Rubinstein, L., Majerová, E., Collins, J. M., Horneffer, Y. R., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0495-3 · Cited by 51
“Semisynthetic geldanamycin derivatives, 17-N-allylamino-17demethoxygeldanamycin (17-AAG, tanespimycin) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, alvespimycin), exhibited improved toxicity profiles and characteristics compared to geldanamycin, but narrow therapeutic indices and lack of clinica…”
BackgroundBayesian refinement of protein structures and ensembles against SAXS data using molecular dynamics
Shevchuk, R., & Hub, J. S. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005800 · Cited by 49
HSP90 is a chaperone for DLK and is required for axon injury signaling
Karney-Grobe, S., Russo, A., Frey, E. N., Milbrandt, J., & DiAntonio, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805351115 · Cited by 49
“An HSP90–client relationship is characterized by two key features: (i) the two proteins physically interact, and (ii) the client protein is degraded with loss of chaperone function (35).”
BackgroundNovel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.
Olson, K. M., Lei, W., Keresztes, A. I., LaVigne, J. E., & Streicher, J. M. (2017) · PubMed Central · Cited by 57
High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer
Zhang, S., Guo, S., Li, Z., Li, D., & Zhan, Q. (2019) · PeerJ · doi:10.7717/peerj.7946 · Cited by 48
Resorcylic acid lactones: A pluripotent scaffold with therapeutic potential
Barluenga, S., Dakas, P., Boulifa, M., Moulin, É., & Winssinger, N. (2008) · Comptes Rendus Chimie · doi:10.1016/j.crci.2008.01.020 · Cited by 48
Potential Vaccines and Post-Exposure Treatments for Filovirus Infections
Friedrich, B. M., Trefry, J. C., Biggins, J. E., Hensley, L. E., Honko, A. N., Smith, D. R., & Olinger, G. G. (2012) · Viruses · doi:10.3390/v4091619 · Cited by 46
“As a result of their many functionalities, Hsp90 inhibitors have been designed to combat diseases such as cancer, and there are currently several drugs now in Phase I and II clinical trials [160,161] Additionally, Hsp90 has shown to be important for replication of negative-strand viruses, as well as HCV, HBV, and poli…”
BackgroundMolecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 46
“Hsp90 is an abundant cellular chaperone whose overexpression in tumor cells correlates with poor prognosis and drug resistance (22).”
BackgroundHsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis
Altieri, D. C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1177-0 · Cited by 46
“The nearly universal exploitation of this pathway in cancer is also known, along with the potential therapeutic opportunities offered by targeting chaperone-directed cellular adaptation [14].”
Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis
Goldstein, M. G., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-5 · Cited by 47
“Heat-shock protein vaccines using conjugated tumor peptides [124,125] and direct HSP90 inhibitors such as 17(Allylamino)-17-demethoxygeldanamycin (17-AAG) [76] have been investigated in clinical trials.”
BackgroundWik, E., Birkeland, E., Trovik, J., Werner, H. M. J., Høivik, E. A., Mjøs, S., Krakstad, C., Kusonmano, K., Mauland, K. K., Stefansson, I. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3413 · Cited by 46
“The top ranked HSP90 inhibitors are shown to be crucial for functional folding of various proteins in multiple pathways, including AKT in the PI3K pathway (47-50).”
Background
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.